Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aftab Khan

Internal Medicine Morris, IL Medical Doctor

NPI 1720073729 CMS profile 78304

425 E US Route 6, Morris, IL 60450

Open in the dashboard

General payments

$7,199

475 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aftab Khan of Morris, IL is reported in the CMS Open Payments database as having received $7,199 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $849 41
2024 General $736 38
2023 General $926 49
2022 General $1,020 63
2021 General $1,157 90
2020 General $1,325 103
2019 General $1,188 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aftab Khan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Aftab Khan were reported at $849. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Aftab Khan Internal Medicine median Middle half National median
2019 $1,188 $159 $48–$570 $163
2020 $1,325 $119 $33–$402 $114
2021 $1,157 $135 $37–$521 $132
2022 $1,020 $141 $42–$496 $149
2023 $926 $149 $45–$519 $160
2024 $736 $154 $47–$537 $164
2025 $849 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $797 49 payments
  2. Pfizer Inc. $750 35 payments
  3. Nestle HealthCare Nutrition Inc. $724 72 payments
  4. Allergan Inc. $720 80 payments
  5. AbbVie, Inc. $615 38 payments
  6. AstraZeneca Pharmaceuticals LP $543 35 payments
  7. Janssen Pharmaceuticals, Inc $376 18 payments
  8. Supernus Pharmaceuticals, Inc. $347 29 payments
  9. Lilly USA, LLC $299 18 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $201 2 payments
  11. Other $1,829 99 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,185 474 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. ZENPEP $724 72 payments
  2. TRELEGY ELLIPTA $663 37 payments
  3. NURTEC ODT $553 25 payments
  4. TROKENDI XR $347 29 payments
  5. ELIQUIS $319 12 payments
  6. VRAYLAR Neuroscience $313 29 payments
  7. VRAYLAR Neuroscience $310 20 payments
  8. ZAVZPRET $256 13 payments
  9. PAXLOVID $249 10 payments
  10. UBRELVY $240 14 payments
  11. Other $4,846 295 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 117 drugs

Part D claims

6,883

Median for Internal Medicine: 777

Drug cost

$426,961

Median for Internal Medicine: $73,373

Branded share of claims

15.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 73 $94,013
Xifaxan Rifaximin Brand 12 $44,309
Ozempic Semaglutide Brand 31 $39,487
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 54 $38,706
Xarelto Rivaroxaban Brand 20 $25,882
Jardiance Empagliflozin Brand 17 $20,127
Rexulti Brexpiprazole Brand 12 $20,122
Linzess Linaclotide Brand 14 $15,223
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 15 $12,943
Trintellix Vortioxetine Hydrobromide Brand 14 $9,567

The 10 drugs with the highest cost, of 117 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$142,632

Of which drugs: $8,006

Medicare patients

376

Average age 71

Services billed

2,413

189 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 42%
Ischemic heart disease 38%
COPD 30%
Heart failure 27%
Depression 26%
Chronic kidney disease 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 16 16 $4,655
Vaccine for influenza for injection into muscle 90662 Office 38 38 $3,109
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 70 $66
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 49 374 $31
Injection, ceftriaxone sodium, per 250 mg J0696 Office 27 48 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $86
  • Otsuka America Pharmaceutical, Inc. $34
$119 12 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $93
$93 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $73
$73 54 —
NURTEC ODT
  • PFIZER INC. $67
$67 — —
ZAVZPRET
  • PFIZER INC. $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record